

# Special Issue

## Nucleic Acid Vaccine

### Message from the Guest Editors

The Special Issue “Nucleic acid vaccines” focuses on the recent scientific and technical progress made in the field of DNA/RNA vaccines will be presented. Most of the viral genomes are either RNA or DNA, encoding the viral proteins. Nucleic acid vaccines mimic natural infection, especially viral infection and, hence, have the ability to elicit both the adaptive and innate immune responses. Moreover, unlike protein-based subunit vaccines, nucleic acid vaccine encoding endogenous antigens are presented by MHC class I, facilitating cellular immune response. We invite authors to share their research on nucleic acid vaccine development with respect to critical aspects not limited to i) design of vaccine with a potential to effectively respond and protect against pandemic pathogens such as COVID-19; ii) safe and effective vaccine delivery technologies; iii) strategies for cost-effective production and storage stability; iv) unique mechanistic insights into vaccine response, efficacy and long-term protection.

---

### Guest Editors

Dr. Sofia Casares

Dr. Himanshu Batra

Dr. Swati Jain

---

### Deadline for manuscript submissions

closed (30 November 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/81540](https://mdpi.com/si/81540)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).